Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.62 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.62 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23907510 | 0.95 | P2RX3 (0.64) | P2RX3P2RX2DNPH1SLC29A1TAS1R3 | |
| SCHEMBL23907433 | 0.92 | P2RX3 (0.61) | P2RX3P2RX2DNPH1SLC29A1TAS1R3 | |
| SCHEMBL23907411 | 0.88 | ADORA3 (0.70) | P2RX3P2RX2DNPH1SLC29A1NT5E | |
| SCHEMBL23907435 | 0.86 | TAS1R3 (0.72) | SLC29A1TAS1R3TAS1R1ADORA1ADORA3 | |
| SCHEMBL23907467 | 0.86 | DNPH1 (0.68) | P2RX3P2RX2DNPH1SLC29A1NT5E | |
| SCHEMBL21839592 | 0.86 | P2RX3 (0.61) | P2RX3P2RX2DNPH1SLC29A1TAS1R3 | |
| SCHEMBL30394180 | 0.86 | P2RX3 (0.61) | P2RX3P2RX2DNPH1SLC29A1TAS1R3 | |
| SCHEMBL23907414 | 0.85 | DNPH1 (0.67) | P2RX3P2RX2DNPH1SLC29A1NT5E | |
| SCHEMBL23907403 | 0.84 | TAS1R3 (0.78) | SLC29A1TAS1R3TAS1R1ADORA1ADORA3 | |
| SCHEMBL23907421 | 0.84 | TAS1R3 (0.75) | SLC29A1TAS1R3TAS1R1ADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | PELOTON THERAPEUTICS INC. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591355-B2 | CD73 inhibitors and uses thereof | ENTPD5, ENTPD1, ENTPD3 | P2RX3 14/4885P2RX2 17/4885DNPH1 1090/4885 |
| US-20210317150-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | P2RX3 37/4885P2RX2 35/4885DNPH1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.